Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization

References

• Cangoz S, Chang YY, Chempakaseril SJ, et al. et al. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther. 2013;38(5):350–9 doi:10.1111/jcpt.12077
   PubMed Web of Science ®Google Scholar
• Van den Heuvel LP, Assink K, Willemsen M, et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet. 2002;111(6):544–7 doi:10.1007/s00439-002-0820-5
   PubMed Web of Science ®Google Scholar
• Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–41 doi:10.2215/CJN.04010609
   PubMed Web of Science ®Google Scholar
• Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304(2):F156–67 doi:10.1152/ajprenal.00409.2012
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–8 doi:10.1111/dom.12081
   PubMed Web of Science ®Google Scholar
• Rosenwasser RF, Rosenwasser JN, Sutton D, et al. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2014;50(11):739–45 doi:10.1358/dot.2014.50112232267
   PubMed Web of Science ®Google Scholar
• Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014;57(5):891–901 doi:10.1007/s00125-014-3196-x
   PubMed Web of Science ®Google Scholar
• Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014;3:212264. doi:10.7573/dic.212264
   PubMedGoogle Scholar
• Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80 doi:10.2147/DDDT.S50773
   PubMed Web of Science ®Google Scholar
• White JR, Jr.. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: A review of the evidence. Ann Pharmacother. 2015; doi:10.1177/1060028015573564
   Web of Science ®Google Scholar
• Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. 2013;1(3):208–219 doi:10.1016/s2213-8587(13)70084-6
   PubMed Web of Science ®Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90 doi:10.1111/j.1463-1326.2011.01517.x
   PubMed Web of Science ®Google Scholar
• Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metabolism and Pharmacokinetics. 2013;28(3):213–219 doi:10.2133/dmpk.DMPK-12-RG-082
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25 doi:10.1007/s40262-013-0126-x
   PubMed Web of Science ®Google Scholar
• Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clinical Pharmacology in Drug Development. 2013;2(2):152–161 doi:10.1002/cpdd.16
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7 doi:10.1038/nature05485
   PubMed Web of Science ®Google Scholar
• Kitade H, Sawamoto K, Nagashimada M, et al. et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes. 2012;61(7):1680–90 doi:10.2337/db11-1506/-/DC1
   PubMed Web of Science ®Google Scholar
• Huh JY, Park YJ, Ham M, et al. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells. 2014;37(5):365–71 doi:10.14348/molcells.2014.0074
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84 doi:10.1172/JCI29881
   PubMed Web of Science ®Google Scholar
• Dey A, Allen J, Hankey-Giblin PA. Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages. Front Immunol. 2014;5:683. doi:10.3389/fimmu.2014.00683
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35 doi:10.1038/nri978
   PubMed Web of Science ®Google Scholar
• Brown BN, Ratner BD, Goodman SB, et al. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials. 2012;33(15).3792–802 doi:10.1016/j.biomaterials.2012.02034
   PubMed Web of Science ®Google Scholar
• Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, et al. Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? Front Immunol. 2014;5:470. doi:10.3389/fimmu.2014.00470
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha_ direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91 doi:10.1126/science.7678183
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30 doi:10.1172/JCI19451
   PubMed Web of Science ®Google Scholar
• Feuerer M, Herrero L, Cipolletta D, et al. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930–9 doi:10.1038/nm.2002
   PubMed Web of Science ®Google Scholar
• Molofsky AB, Nussbaum JC, Liang HE, et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med. 2013;210(3):535–49 doi:10.1084/jem.20121964
   PubMed Web of Science ®Google Scholar
• Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45 doi:10.1146/annurev-immunol-031210-101322
   PubMed Web of Science ®Google Scholar
• Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology. 2014;59(5):2034–42 doi:10.1002/hep.26754
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46 doi:10.1146/annurev-physiol-021909-135846
   PubMed Web of Science ®Google Scholar
• Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. Science. 2013;342(6161):1242974. doi:10.1126/science.1242974
   PubMed Web of Science ®Google Scholar
• Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95 doi:10.1172/JCI59643
   PubMed Web of Science ®Google Scholar
• Jager J, Aparicio-Vergara M, Aouadi M. Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells. J Intern Med. 2016;280(2):209–20 doi:10.1111/joim.12483
   PubMed Web of Science ®Google Scholar
• Xu L, Kitade H, Ni Y, et al. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules. 2015;5(3):1563–79 doi:10.3390/biom5031563
   PubMed Web of Science ®Google Scholar
• Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389(6651):610–4 doi:10.1038/39335
   PubMed Web of Science ®Google Scholar
• Tahara A, Kurosaki E, Yokono M, et al. et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1-3):246–55 doi:10.1016/j.ejphar.2013.05.014
   PubMed Web of Science ®Google Scholar
• Terami N, Ogawa D, Tachibana H, et al. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777. doi:10.1371/journal.pone.0100777
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149 doi:10.1016/j.ebiom.2017.05.028
   PubMed Web of Science ®Google Scholar
• Haslam DW, James WPT. Obesity. The Lancet. 2005;366(9492):1197–1209 doi:10.1016/s0140-6736(05)67483-1
   PubMed Web of Science ®Google Scholar
• Obata A, Kubota N, Kubota T, et al. et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016;157(3):1029–42 doi:10.1210/en.2015-1588
   PubMed Web of Science ®Google Scholar
• Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20(8):1645–52 doi:10.1038/oby.2012.59
   PubMed Web of Science ®Google Scholar
• Nakano S, Katsuno K, Isaji M, et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol. 2015;5(3):190–8 doi:10.1016/j.jceh.2015.02.005
   PubMed Web of Science ®Google Scholar
• Qiang S, Nakatsu Y, Seno Y, et al. et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015;7:104. doi:10.1186/s13098-015-0102-8
   PubMed Web of Science ®Google Scholar
• Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032–8 doi:10.2337/db16-0049
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose votransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–1195 doi:10.2337/db15-1356
   PubMed Web of Science ®Google Scholar
• Hawley SA, Ford RJ, Smith BK, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–94 doi:10.2337/db16-0058
   PubMed Web of Science ®Google Scholar
• Adya R, Tan BK, Randeva HS. Differential effects of leptin and adiponectin in endothelial angiogenesis. J Diabetes Res. 2015;2015:648239. doi:10.1155/2015/648239
   PubMedGoogle Scholar
• Lowell BB, Spiegelman BM. Towards a molecular understanding of adaptive thermogenesis. Nature. 2000;404(6778):652–60 doi:10.1038/35007527
   PubMed Web of Science ®Google Scholar
• Cohen P, Levy JD, Zhang Y, et al. et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell. 2014;156(1-2):304–16 doi:10.1016/j.cell.2013.12.021
   PubMed Web of Science ®Google Scholar
• Seale P, Bjork B, Yang W, et al. et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008;454(7207):961–7 doi:10.1038/nature07182
   PubMed Web of Science ®Google Scholar
• Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev. 2013;27(3):234–50 doi:10.1101/gad.211649.112
   PubMed Web of Science ®Google Scholar
• Lo KA, Sun L. Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes. Biosci Rep. 2013;33(5): doi:10.1042/BSR20130046
   PubMedGoogle Scholar
• Nguyen KD, Qiu Y, Cui X, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480(7375):104–8 doi:10.1038/nature10653
   PubMed Web of Science ®Google Scholar
• Qiu Y, Nguyen KD, Odegaard JI, et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell. 2014;157(6):1292–308 doi:10.1016/j.cell.2014.03.066
   PubMed Web of Science ®Google Scholar
• Hui X, Gu P, Zhang J, et al. et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 2015;22(2):279–90 doi:10.1016/j.cmet.2015.06.004
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gao P, Sun F, et al. et al. Sodium intake regulates glucose homeostasis through the PPARdelta/adiponectin-mediated SGLT2 pathway. Cell Metab. 2016;23(4):699–711 doi:10.1016/j.cmet.2016.02.019
   PubMed Web of Science ®Google Scholar
• Tanizawa Y, Araki E, Tobe K, et al. Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes. Diabetologia. 2013;56:S82–S83
   PubMed Web of Science ®Google Scholar
• Inagaki T, Dutchak P, Zhao G, et al. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–25 doi:10.1016/j.cmet.2007.05.003
   PubMed Web of Science ®Google Scholar
• Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–37 doi:10.1016/j.cmet.2007.05.002
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, et al. et al. FGF21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–35 doi:10.1172/JCI23606
   PubMed Web of Science ®Google Scholar
• Fisher FM, Kleiner S, Douris N, et al. et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26(3):271–81 doi:10.1101/gad.177857.111
   PubMed Web of Science ®Google Scholar